Immunogenicity, efficacy and safety of Nuwiq<sup>®</sup> (human‐cl rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

201727 citationsJournal Articlehybrid Open Access

Authors

Ri Liesner · Great Ormond Street Hospital

Marina Abashidze · Russian Research Institute of Hematology and Transfusiology

Olga Aleinikova · Republican Scientific and Practical Center of Cardiology

Carmen Altisent · Vall d'Hebron Hospital Universitari

Mark Belletrutti · University of Alberta

Annie Borel‐Derlon · Centre Hospitalier Universitaire de Caen Normandie

Manuel Carção

Abstract

These interim data show a cumulative incidence of 12.8% for HT inhibitors and convincing efficacy and tolerability in PUPs treated with Nuwiq<sup>®</sup> .

Topics & Keywords

Hemophilia Treatment and Research Platelet Disorders and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Haemophilia

Volume 24, Issue 2, pp. 211-220

DOI: 10.1111/hae.13320

Field-Weighted Citation Impact: 2.63